OraSure Technologies has conducted a study that suggests self-sampling with its Colli-Pee® device is a cost-effective alternative to clinician-collected sampling and other self-sampling methods for routine human papillomavirus (HPV) primary cervical cancer screening. The study, published in the biomedical journal “BMJ Open,” indicates that if self-screening led to a 15% increase in women accessing the HPV cervical cancer screening program in England, along with an additional 50% transition to self-screening by women currently undergoing screening in physician practices, the UK National Health Service Cervical Screening Programme could potentially save £19.2m per year through minimally invasive first-void urine self-screening or £16.5m per year through more invasive vaginal swab-based self-screening. The Colli-Pee® first-void urine collection device evaluated in the study is manufactured by OraSure's Belgium-based subsidiary, Novosanis.
Keywords: OraSure Technologies, Colli-Pee® device, HPV screening, cost-effective, self-sampling
The study found that self-sampling with the Colli-Pee® device offers a more affordable alternative to clinician-collected sampling and other self-sampling methods for routine human papill